Research Grade Bemarituzumab

Bemarituzumab (bema), a first-in-class humanized IgG1 monoclonal antibody, selectively binds to 2b Isoform of thefibroblast growth factor receptor (FGFR2b) . Bemarituzumab (FPA144) is a first-in-class humanized immunoglobulin G1 monoclonal antibody specific to the splice-variant FGFR2b that inhibits binding of the ligands FGF7, FGF10, and FGF22. Specifically, bemarituzumab does not inhibit binding of FGF23, the ligand responsible for phosphate and vitamin D metabolism, thereby potentially avoiding the risk of hyperphosphatemia associated with pan-FGFR tyrosine kinase inhibitors. Bemarituzumab is also glycoengineered for increased affinity for the human Fc gamma RIIIA receptor expressed on natural killer cells, enabling enhanced antibody-dependent cell_x0002_mediated cytotoxicity.